REFERENCES
1. Mehta A, Beck M, Eyskens F, et al. Fabry disease: a review of current management strategies. QJM 2010;103:641-59.
3. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236-42.
4. AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales). [Evaluation of patients with Fabry disease in Argentina]. Medicina 2010;70:37-43. (in Spanish).
5. Giugliani R, Niu D, Ramaswami U, et al. A 15-year perspective of the fabry outcome survey. J Inborn Errors Metab Screen 2016;4:e160041.
6. Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 2006;79:31-40.
7. Lin HY, Chong KW, Hsu JH, et al. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet 2009;2:450-6.
8. Marchesoni CL, Roa N, Pardal AM, et al. Misdiagnosis in Fabry disease. J Pediatr 2010;156:828-31.
9. Reisin R, Perrin A, García-Pavía P. Time delays in the diagnosis and treatment of Fabry disease. Int J Clin Pract 2017;71:e12914.
10. von Scheidt W, Eng CM, Fitzmaurice TF, et al. An atypical variant of Fabry’s disease with manifestations confined to the myocardium. N Engl J Med 1991;324:395-9.
11. Nakao S, Kodama C, Takenaka T, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int 2003;64:801-7.
12. Rolfs A, Fazekas F, Grittner U, et al. Stroke in Young Fabry Patients (sifap) Investigators. Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study. Stroke 2013;44:340-9.
13. Wanner C, Arad M, Baron R, et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab 2018;124:189-203.
14. Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-9.
15. Eng CM, Guffon N, Wilcox WR, et al. International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry’s disease. N Engl J Med 2001;345:9-16.
16. Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry’s disease with the pharmacologic chaperone migalastat. N Engl J Med 2016;375:545-55.
18. Moore DF, Kaneski CR, Askari H, Schiffmann R. The cerebral vasculopathy of Fabry disease. J Neurol Sci 2007;257:258-63.
19. Joly DA, Grünfeld JP. 3-Nitrotyrosine as a biomarker for vascular involvement in Fabry disease. Kidney Int 2014;86:5-7.
20. Shu L, Vivekanandan-Giri A, Pennathur S, et al. Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease. Kidney Int 2014;86:58-66.
21. Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H. Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol 2004;251:564-70.
22. Moore DF, Altarescu G, Ling GSF, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002;33:525-31.
23. Biancini GB, Vanzin CS, Rodrigues DB, et al. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochim Biophys Acta 2012;1822:226-32.
24. Simoncini C, Torri S, Montano V, et al. Oxidative stress biomarkers in Fabry disease: is there a room for them? J Neurol 2020;267:3741-52.
25. Rozenfeld P, Feriozzi S. Contribution of inflammatory pathways to Fabry disease pathogenesis. Mol Genet Metab 2017;122:19-27.
26. Spada FM, Koezuka Y, Porcelli SA. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med 1998;188:1529-34.
27. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 2002;195:625-36.
28. O’Reilly V, Zeng SG, Bricard G, et al. Distinct and overlapping effector functions of expanded human CD4+, CD8α+ and CD4-CD8α- invariant natural killer T cells. PLoS One 2011;6:e28648.
29. Reisin RC, Rozenfeld P, Bonardo P. Fabry disease patients have an increased risk of stroke in the COVID-19 ERA. A hypothesis. Med Hypotheses 2020;144:110282.
31. Biancini GB, Jacques CE, Hammerschmidt T, et al. Biomolecules damage and redox status abnormalities in Fabry patients before and during enzyme replacement therapy. Clin Chim Acta 2016;461:41-6.
32. Kang JJ, Kaissarian NM, Desch KC, et al. α-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease. Kidney Int 2019;95:149-59.
33. DeGraba T, Azhar S, Dignat-George F, et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 2000;47:229-33.
34. Shen JS, Meng XL, Moore DF, et al. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab 2008;95:163-8.
35. Park S, Kim JA, Joo KY, et al. Globotriaosylceramide leads to KCa3.1 channel dysfunction: a new insight into endothelial dysfunction in Fabry disease. Cardiovasc Res 2011;89:290-9.
36. Choi S, Kim JA, Na HY, et al. Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in fabry disease. Arterioscler Thromb Vasc Biol 2014;34:81-9.
37. Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 2008;105:2812-7.
38. Rombach SM, Twickler TB, Aerts JM, Linthorst GE, Wijburg FA, Hollak CE. Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab 2010;99:99-108.
39. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 2007;21:20-7.
40. Cavanagh EM, Ferder M, Inserra F, Ferder L. Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint. Am J Physiol Heart Circ Physiol 2009;296:H550-8.
41. Mishra V, Banerjee A, Gandhi AB, et al. Stroke and Fabry disease: a review of literature. Cureus 2020;12:e12083.
42. Lam YLT, Sheng B, Kwok HM, Yu ELM, Ma KFJ. Basilar artery diameter as neuroimaging biomarker in Chinese Fabry disease patients. Orphanet J Rare Dis 2023;18:186.
43. Uçeyler N, Homola GA, Guerrero González H, et al. Increased arterial diameters in the posterior cerebral circulation in men with Fabry disease. PLoS One 2014;9:e87054.
44. Fellgiebel A, Keller I, Martus P, et al. Basilar artery diameter is a potential screening tool for Fabry disease in young stroke patients. Cerebrovasc Dis 2011;31:294-9.
45. Pico F, Labreuche J, Touboul PJ, Leys D, Amarenco P. Intracranial arterial dolichoectasia and small-vessel disease in stroke patients. Ann Neurol 2005;57:472-9.
46. Zhang DP, Yin S, Zhang HL, Li D, Song B, Liang JX. Association between intracranial arterial dolichoectasia and cerebral small vessel disease and its underlying mechanisms. J Stroke 2020;22:173-84.
47. Mehta A, Clarke JT, Giugliani R, et al. FOS Investigators. Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet 2009;46:548-52.
48. Hagège A, Réant P, Habib G, et al. Fabry disease in cardiology practice: Literature review and expert point of view. Arch Cardiovasc Dis 2019;112:278-87.
49. Weidemann F, Breunig F, Beer M, et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 2005;26:1221-7.
50. Kampmann C, Wiethoff CM, Perrot A, Beck M, Dietz R, Osterziel KJ. The heart in Anderson Fabry disease. Z Kardiol 2002;91:786-95.
51. Weidemann F, Maier SKG, Störk S, et al. Usefulness of an implantable loop recorder to detect clinically relevant arrhythmias in patients with advanced Fabry cardiomyopathy. Am J Cardiol 2016;118:264-74.
52. Beck M, Cox TM. Comment: why are females with Fabry disease affected? Mol Genet Metab Rep 2019;21:100529.
53. Fuller M, Mellett N, Hein LK, Brooks DA, Meikle PJ. Absence of α-galactosidase cross-correction in Fabry heterozygote cultured skin fibroblasts. Mol Genet Metab 2015;114:268-73.
54. Dobyns WB, Filauro A, Tomson BN, et al. Inheritance of most X-linked traits is not dominant or recessive, just X-linked. Am J Med Genet A 2004;129A:136-43.
55. Kolodny E, Fellgiebel A, Hilz MJ, et al. Cerebrovascular involvement in Fabry disease: current status of knowledge. Stroke 2015;46:302-13.
56. Mitsias P, Levine SR. Cerebrovascular complications of Fabry’s disease. Ann Neurol 1996;40:8-17.
57. Mehta A, Hughes DA. Fabry disease. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1292/. [Last accessed on 21 March 2024].
58. Morgan SH, Rudge P, Smith SJ, et al. The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency) - investigation of symptomatic and presymptomatic patients. Q J Med 1990;75:491-507.
60. Buechner S, Moretti M, Burlina AP, et al. Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry 2008;79:1249-54.
61. Galanos J, Nicholls K, Grigg L, Kiers L, Crawford A, Becker G. Clinical features of Fabry’s disease in Australian patients. Intern Med J 2002;32:575-84.
62. Vedder AC, Linthorst GE, van Breemen MJ, et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 2007;30:68-78.
63. Utsumi K, Ueda K, Watanabe M, et al. Thrombosis in Japanese patients with Fabry disease. J Neurol Sci 2009;283:83-5.
64. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38:769-75.
65. MacDermot KD, Holmes A, Miners AH. Natural history of Fabry disease in affected males and obligate carrier females. J Inherit Metab Dis 2001;24:13-4.
66. Gupta S, Ries M, Kotsopoulos S, Schiffmann R. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine 2005;84:261-8.
67. Mehta A, Ginsberg L. FOS Investigators. Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatr Suppl 2005;94:24-7.
68. Ginsberg L. Nervous system manifestations of Fabry disease: data from FOS - the Fabry Outcome Survey. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 23.
69. Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 2009;40:788-94.
70. Vijapurapu R, Roy A, Demetriades P, et al. Systematic review of the incidence and clinical risk predictors of atrial fibrillation and permanent pacemaker implantation for bradycardia in Fabry disease. Open Heart 2023;10:e002316.
71. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129:837-47.
72. Rolfs A, Böttcher T, Zschiesche M, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 2005;366:1794-6.
73. Shi Q, Chen J, Pongmoragot J, Lanthier S, Saposnik G. Prevalence of Fabry disease in stroke patients - a systematic review and meta-analysis. J Stroke Cerebrovasc Dis 2014;23:985-92.
74. Marquardt L, Baker R, Segal H, et al. Fabry disease in unselected patients with TIA or stroke: population-based study. Eur J Neurol 2012;19:1427-32.
75. Reisin RC, Mazziotti J, Cejas LL, et al. AISYF Investigators. Prevalence of Fabry disease in young patients with stroke in Argentina. J Stroke Cerebrovasc Dis 2018;27:575-82.
76. Doheny D, Srinivasan R, Pagant S, Chen B, Yasuda M, Desnick RJ. Fabry Disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995-2017. J Med Genet 2018;55:261-8.
77. Härtl J, Hartberger J, Wunderlich S, et al. Regeneron Genetics Center. Exome-based gene panel analysis in a cohort of acute juvenile ischemic stroke patients:relevance of NOTCH3 and GLA variants. J Neurol 2023;270:1501-11.
78. Palaiodimou L, Stefanou MI, Bakola E, et al. D313Y variant in Fabry disease: a systematic review and meta-analysis. Neurology 2022;99:e2188-200.
80. Kono Y, Wakabayashi T, Kobayashi M, et al. Characteristics of cerebral microbleeds in patients with Fabry disease. J Stroke Cerebrovasc Dis 2016;25:1320-5.
81. Cocozza S, Russo C, Pontillo G, Pisani A, Brunetti A. Neuroimaging in Fabry disease: current knowledge and future directions. Insights Imaging 2018;9:1077-88.
82. Reisin RC, Romero C, Marchesoni C, et al. Brain MRI findings in patients with Fabry disease. J Neurol Sci 2011;305:41-4.
83. Brooks JBB, Fragoso YD. Neurological manifestations in Fabry disease. Neuroimmunol Neuroinflammation 2016;3:228.
84. Fellgiebel A, Müller MJ, Mazanek M, Baron K, Beck M, Stoeter P. White matter lesion severity in male and female patients with Fabry disease. Neurology 2005;65:600-2.
85. Kaye EM, Kolodny EH, Logigian EL, Ullman MD. Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation. Ann Neurol 1988;23:505-9.
86. Marchesoni C, Cisneros E, Pfister P, et al. Brain MRI findings in children and adolescents with Fabry disease. J Neurol Sci 2018;395:131-4.
87. Shribman SE, Shah AR, Werring DJ, Cockerell OC. Fabry disease mimicking multiple sclerosis: lessons from two case reports. Mult Scler Relat Disord 2015;4:170-5.
88. Rath J, Foesleitner O, Haider L, et al. Neuroradiological differentiation of white matter lesions in patients with multiple sclerosis and Fabry disease. Orphanet J Rare Dis 2022;17:37.
89. Cocozza S, Olivo G, Riccio E, et al. Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis. Neuroradiology 2017;59:563-70.
90. Böttcher T, Rolfs A, Tanislav C, et al. Fabry disease - underestimated in the differential diagnosis of multiple sclerosis? PLoS One 2013;8:e71894.
91. Lyndon D, Davagnanam I, Wilson D, et al. MRI-visible perivascular spaces as an imaging biomarker in Fabry disease. J Neurol 2021;268:872-8.
92. Moore DF, Ye F, Schiffmann R, Butman JA. Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. AJNR Am J Neuroradiol 2003;24:1096-101.
93. Takanashi J, Barkovich AJ, Dillon WP, Sherr EH, Hart KA, Packman S. T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease. AJNR Am J Neuroradiol 2003;24:916-21.
94. Burlina AP, Manara R, Caillaud C, et al. The pulvinar sign: frequency and clinical correlations in Fabry disease. J Neurol 2008;255:738-44.
95. Cocozza S, Russo C, Pisani A, et al. Redefining the pulvinar sign in Fabry disease. AJNR Am J Neuroradiol 2017;38:2264-9.
96. Manara R, Carlier RY, Righetto S, et al. Basilar artery changes in Fabry disease. AJNR Am J Neuroradiol 2017;38:531-6.
97. Fazekas F, Enzinger C, Schmidt R, et al; SIFAP 1 Investigators. Brain magnetic resonance imaging findings fail to suspect Fabry disease in young patients with an acute cerebrovascular event. Stroke 2015;46:1548-53.
98. Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab 2018;123:416-27.
99. Germain DP, Fouilhoux A, Decramer S, et al. Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients. Clin Genet 2019;96:107-17.
100. Pontillo G, Cocozza S, Brunetti A, et al. Reduced intracranial volume in Fabry disease: evidence of abnormal neurodevelopment? Front Neurol 2018;9:672.
101. Paavilainen T, Lepomäki V, Saunavaara J, et al. Diffusion tensor imaging and brain volumetry in Fabry disease patients. Neuroradiology 2013;55:551-8.
102. Fellgiebel A, Mazanek M, Whybra C, et al. Pattern of microstructural brain tissue alterations in Fabry disease: a diffusion-tensor imaging study. J Neurol 2006;253:780-7.
103. Tedeschi G, Bonavita S, Banerjee TK, Virta A, Schiffmann R. Diffuse central neuronal involvement in Fabry disease: a proton MRS imaging study. Neurology 1999;52:1663-7.
104. Gabusi I, Pontillo G, Petracca M, et al. Structural disconnection and functional reorganization in Fabry disease: a multimodal MRI study. Brain Commun 2022;4:fcac187.
105. Elstein D, Doniger GM, Altarescu G. Cognitive testing in Fabry disease: pilot using a brief computerized assessment tool. Isr Med Assoc J 2012;14:624-8.
106. Segal P, Kohn Y, Pollak Y, Altarescu G, Galili-Weisstub E, Raas-Rothschild A. Psychiatric and cognitive profile in Anderson-Fabry patients: a preliminary study. J Inherit Metab Dis 2010;33:429-36.
107. Mendez MF, Stanley TM, Medel NM, Li Z, Tedesco DT. The vascular dementia of Fabry’s disease. Dement Geriatr Cogn Disord 1997;8:252-7.
108. Okeda R, Nisihara M. An autopsy case of Fabry disease with neuropathological investigation of the pathogenesis of associated dementia. Neuropathology 2008;28:532-40.
109. Loeb J, Feldt-rasmussen U, Madsen CV, Vogel A. Cognitive impairments and subjective cognitive complaints in Fabry disease: a nationwide study and review of the literature. JIMD Rep 2018;41:73-80.
110. Sigmundsdottir L, Tchan MC, Knopman AA, Menzies GC, Batchelor J, Sillence DO. Cognitive and psychological functioning in Fabry disease. Arch Clin Neuropsychol 2014;29:642-50.
111. Körver S, Geurtsen GJ, Hollak CEM, et al. Cognitive functioning and depressive symptoms in Fabry disease: a follow-up study. J Inherit Metab Dis 2020;43:1070-81.
112. Anderson JF, Saling MM, Srikanth VK, Thrift AG, Donnan GA. Individuals with first-ever clinical presentation of a lacunar infarction syndrome: Is there an increased likelihood of developing mild cognitive impairment in the first 12 months after stroke? J Neuropsychol 2008;2:373-85.
113. Lelieveld IM, Böttcher A, Hennermann JB, Beck M, Fellgiebel A. Eight-year follow-up of neuropsychiatric symptoms and brain structural changes in Fabry disease. PLoS One 2015;10:e0137603.
114. Löhle M, Hughes D, Milligan A, et al. Clinical prodromes of neurodegeneration in Anderson-Fabry disease. Neurology 2015;84:1454-64.
115. Loret G, Miatton M, Vingerhoets G, Poppe B, Hemelsoet D. A long-term neuropsychological evaluation in Fabry disease. Acta Neurol Belg 2021;121:191-7.
116. Schermuly I, Müller MJ, Müller KM, et al. Neuropsychiatric symptoms and brain structural alterations in Fabry disease. Eur J Neurol 2011;18:347-53.
117. Wadley VG, Mcclure LA, Warnock DG, et al. Cognitive function in adults aging with Fabry disease: a case - control feasibility study using telephone-based assessments. JIMD Rep 2015;18:41-50.
118. Cociasu I, Sorbera C, Tuttolomondo A, Morgante F. Anderson-Fabry disease: a rare cause of levodopa-responsive early-onset Parkinsonism. Mov Disord Clin Pract 2021;8:S32-4.
119. Kahn P. Anderson-Fabry disease: a histopathological study of three cases with observations on the mechanism of production of pain. J Neurol Neurosurg Psychiatry 1973;36:1053-62.
120. Zedde M, Pascarella R, Cavallieri F, et al. Anderson-Fabry disease: a new piece of the lysosomal puzzle in Parkinson disease? Biomedicines 2022;10:3132.
121. Schiffmann R, Rapkiewicz A, Abu-Asab M, et al. Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch 2006;448:337-43.
122. Ortiz A, Abiose A, Bichet DG, et al. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry. J Med Genet 2016;53:495-502.
123. Sheng S, Wu L, Nalleballe K, et al. Fabry’s disease and stroke: Effectiveness of enzyme replacement therapy (ERT) in stroke prevention, a review with meta-analysis. J Clin Neurosci 2019;65:83-6.
124. Fellgiebel A, Gartenschläger M, Wildberger K, Scheurich A, Desnick RJ, Sims K. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease. Cerebrovasc Dis 2014;38:448-56.
125. Rost NS, Cloonan L, Kanakis AS, et al. Determinants of white matter hyperintensity burden in patients with Fabry disease. Neurology 2016;86:1880-6.
126. Lenders M, Karabul N, Duning T, et al. Thromboembolic events in Fabry disease and the impact of factor V Leiden. Neurology 2015;84:1009-16.
127. Ferrari G, Reisin R, Kisinovsky I, et al. Major cardiovascular adverse events in Fabry disease patients receiving agalsidase alfa. Medicina 2021;81:173-9.
128. Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006;8:539-48.
129. Fazekas F, Enzinger C, Schmidt R, et al. sifap1 Investigators. MRI in acute cerebral ischemia of the young: the Stroke in Young Fabry Patients (sifap1) Study. Neurology 2013;81:1914-21.
